PALB2 Gene Mutation Clinical Trials

6 recruitingLast updated: June 17, 2026

There are 6 actively recruiting palb2 gene mutation clinical trials across 3 countries. Studies span Phase 1, Not Applicable, Phase 2, Phase 3. Top locations include New York, New York, United States, San Francisco, California, United States, Commack, New York, United States. Updated daily from ClinicalTrials.gov.


PALB2 Gene Mutation Trials at a Glance

6 actively recruiting trials for palb2 gene mutation are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in New York, San Francisco, and Commack. Lead sponsors running palb2 gene mutation studies include General Oncology, Inc., Institute of Cancer Research, United Kingdom, and Memorial Sloan Kettering Cancer Center.

Browse palb2 gene mutation trials by phase

Treatments under study

About PALB2 Gene Mutation Clinical Trials

Looking for clinical trials for PALB2 Gene Mutation? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PALB2 Gene Mutation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PALB2 Gene Mutation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BRCA MutationBRCA1 MutationBRCA2 Mutation+3 more
Varun Monga, MBBS18 enrolled1 locationNCT06177171
Recruiting
Phase 1

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Metastatic Solid TumorBRCA1 MutationBRCA2 Mutation+2 more
University of California, San Francisco24 enrolled1 locationNCT05694715
Recruiting
Phase 1

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Breast Cancer MetastaticHER2-Negative Breast CarcinomaPancreatic Cancer+17 more
General Oncology, Inc.24 enrolled2 locationsNCT04150042
Recruiting

The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.

Prostate CancerBRCA MutationATM Gene Mutation+4 more
Institute of Cancer Research, United Kingdom50 enrolled1 locationNCT05097274
Recruiting
Phase 2Phase 3

Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer

PALB2 Gene MutationPancreatic Cancer, Advanced or MetastaticBRCA1/2 Mutation
University Health Network, Toronto10 enrolled1 locationNCT06783140
Recruiting
Not Applicable

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

BRCA1 MutationBRCA2 MutationPOLD1 Gene Mutation+19 more
Memorial Sloan Kettering Cancer Center1,000 enrolled8 locationsNCT05420064